{"id":933531,"date":"2026-02-03T07:04:47","date_gmt":"2026-02-03T12:04:47","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-participate-in-the-guggenheim-emerging-outlook-biotech-summit\/"},"modified":"2026-02-03T07:04:47","modified_gmt":"2026-02-03T12:04:47","slug":"foghorn-therapeutics-to-participate-in-the-guggenheim-emerging-outlook-biotech-summit","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-participate-in-the-guggenheim-emerging-outlook-biotech-summit\/","title":{"rendered":"Foghorn Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">WATERTOWN, Mass., Feb.  03, 2026  (GLOBE NEWSWIRE) &#8212; Foghorn\u00ae Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in the Guggenheim Emerging Outlook: Biotech Summit, being held February 11-12, 2026, in New York, NY. With an initial focus in oncology, Foghorn\u2019s Gene Traffic Control\u00ae platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.<\/p>\n<p align=\"left\">\n        <strong>Presentation Date and Time: <\/strong>Wednesday February 11, 2026, at 3:00 p.m. EST<\/p>\n<ul type=\"disc\">\n<li>Presenter: Adrian Gottschalk, President and Chief Executive Officer<\/li>\n<li>Please find a link to the webcast <a href=\"https:\/\/nam04.safelinks.protection.outlook.com\/?url=https%3A%2F%2Fevent.summitcast.com%2Fview%2Fkbtj9ZAiVkB78KPZiu5dZ9%2FkG7rXWs4bgH8qKwXBzQzLZ&amp;data=05%7C02%7Cafolias%40lifesciadvisors.com%7Cb0090486d657460217d208de59bca6ce%7C65ec683a30ce43d0a6ef2fd46d0f5e8a%7C0%7C0%7C639046864024889825%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&amp;sdata=f2ceO2lB%2BPTAXfgGy%2Bd8LOJYjPsnx37%2BUzOott6O9Sk%3D&amp;reserved=0\" rel=\"nofollow\" target=\"_blank\">here<\/a><\/li>\n<li>Management will also participate in one-on-one meetings<\/li>\n<\/ul>\n<p align=\"left\">A webcast of the presentation can be accessed under \u201cEvents &amp; Presentations\u201d in the Investors section of the Company\u2019s website,\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=IQfw83yFhU06X9b-2eoNudOQ8Y1ZvOigK7x76_bZc2jgkqwNNtFAsqtjY1UtZ0CJVIl56PKQzPHT5YZGkV5pJR6a-c1eE6Mo132J2jeNx8-hBV8bmfe5ljUH2wIuAAZ6CazzGasR0Pmn7OQjdR84fw-ebTG5ftkeuM-R3mdqtYdu5O8ppqkxdjm93ohk27Q_6-nKtJmBExnSMr30Mz0Gow5JFCPEM3cLvy_bt4K9EkV4EjZ1kjCYwjS5RmPMhWTbMcDWwtd-E0H-r3f50J5aXA==\" rel=\"nofollow\" target=\"_blank\">www.foghorntx.com<\/a>, and will be available for 30 days.<\/p>\n<p align=\"left\">\n        <strong>About Foghorn Therapeutics<\/strong><br \/>\n        <br \/>Foghorn<sup>\u00ae<\/sup> Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary, scalable Gene Traffic Control<sup>\u00ae<\/sup> platform, Foghorn is systematically studying, identifying, and validating potential drug targets within the chromatin regulatory system. The Company is developing multiple product candidates in oncology. Visit our website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=IQfw83yFhU06X9b-2eoNuZErqkmG_s8rooJK7UzSaCeEJjVR1h4VVFb4PjWgS8_BjNBrCYQs3qY25rtkQmkZmssn29xbuEMzEFT40snRXzE=\" rel=\"nofollow\" target=\"_blank\">www.foghorntx.com<\/a> for more information on the Company, and follow us on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=lEhVsIhc6NGqC_P3OYwY8Sxkg5e3Y9CqKPRTOc9JefV0ZSY_kFRv64bOWvqe8j4MzYVZQqWZJT5fTIVGfZ23IA==\" rel=\"nofollow\" target=\"_blank\">X<\/a> and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=szrwfQSk4766PX_PV711-2-dD1fPB8KPRl8SKPkMfWPoZWgethvAC4C2QA1wIW_gsDlmPttQYz8r0Wx_M1w0cq3P_bSgy64x9hrKRBYuDK-Kzm0P7f8XtY-sCwTjyVql\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a>.<\/p>\n<p align=\"left\">\n        <strong>Contact:<\/strong><br \/>\n        <br \/>Karin Hellsvik, Foghorn Therapeutics Inc. <u>khellsvik@foghorntx.com<\/u><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY0NTY2NCM3Mzk5ODc4IzIyMDI4NjI=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/YzBkZTAzZTctNDU3NS00YmFhLWI1MDgtYjYzNzM5ZjI3YzJmLTEyMTQ0MTUtMjAyNi0wMi0wMy1lbg==\/tiny\/Foghorn-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>WATERTOWN, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) &#8212; Foghorn\u00ae Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in the Guggenheim Emerging Outlook: Biotech Summit, being held February 11-12, 2026, in New York, NY. With an initial focus in oncology, Foghorn\u2019s Gene Traffic Control\u00ae platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases. Presentation Date and Time: Wednesday February 11, 2026, at 3:00 p.m. EST Presenter: Adrian Gottschalk, President and Chief Executive Officer Please find a link to the webcast here Management will also participate in one-on-one meetings &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-participate-in-the-guggenheim-emerging-outlook-biotech-summit\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Foghorn Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-933531","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Foghorn Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-participate-in-the-guggenheim-emerging-outlook-biotech-summit\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Foghorn Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"WATERTOWN, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) &#8212; Foghorn\u00ae Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in the Guggenheim Emerging Outlook: Biotech Summit, being held February 11-12, 2026, in New York, NY. With an initial focus in oncology, Foghorn\u2019s Gene Traffic Control\u00ae platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases. Presentation Date and Time: Wednesday February 11, 2026, at 3:00 p.m. EST Presenter: Adrian Gottschalk, President and Chief Executive Officer Please find a link to the webcast here Management will also participate in one-on-one meetings &hellip; Continue reading &quot;Foghorn Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-participate-in-the-guggenheim-emerging-outlook-biotech-summit\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-03T12:04:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY0NTY2NCM3Mzk5ODc4IzIyMDI4NjI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foghorn-therapeutics-to-participate-in-the-guggenheim-emerging-outlook-biotech-summit\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foghorn-therapeutics-to-participate-in-the-guggenheim-emerging-outlook-biotech-summit\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Foghorn Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit\",\"datePublished\":\"2026-02-03T12:04:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foghorn-therapeutics-to-participate-in-the-guggenheim-emerging-outlook-biotech-summit\\\/\"},\"wordCount\":241,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foghorn-therapeutics-to-participate-in-the-guggenheim-emerging-outlook-biotech-summit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY0NTY2NCM3Mzk5ODc4IzIyMDI4NjI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foghorn-therapeutics-to-participate-in-the-guggenheim-emerging-outlook-biotech-summit\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foghorn-therapeutics-to-participate-in-the-guggenheim-emerging-outlook-biotech-summit\\\/\",\"name\":\"Foghorn Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foghorn-therapeutics-to-participate-in-the-guggenheim-emerging-outlook-biotech-summit\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foghorn-therapeutics-to-participate-in-the-guggenheim-emerging-outlook-biotech-summit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY0NTY2NCM3Mzk5ODc4IzIyMDI4NjI=\",\"datePublished\":\"2026-02-03T12:04:47+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foghorn-therapeutics-to-participate-in-the-guggenheim-emerging-outlook-biotech-summit\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foghorn-therapeutics-to-participate-in-the-guggenheim-emerging-outlook-biotech-summit\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foghorn-therapeutics-to-participate-in-the-guggenheim-emerging-outlook-biotech-summit\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY0NTY2NCM3Mzk5ODc4IzIyMDI4NjI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY0NTY2NCM3Mzk5ODc4IzIyMDI4NjI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foghorn-therapeutics-to-participate-in-the-guggenheim-emerging-outlook-biotech-summit\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Foghorn Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Foghorn Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-participate-in-the-guggenheim-emerging-outlook-biotech-summit\/","og_locale":"en_US","og_type":"article","og_title":"Foghorn Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit - Market Newsdesk","og_description":"WATERTOWN, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) &#8212; Foghorn\u00ae Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in the Guggenheim Emerging Outlook: Biotech Summit, being held February 11-12, 2026, in New York, NY. With an initial focus in oncology, Foghorn\u2019s Gene Traffic Control\u00ae platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases. Presentation Date and Time: Wednesday February 11, 2026, at 3:00 p.m. EST Presenter: Adrian Gottschalk, President and Chief Executive Officer Please find a link to the webcast here Management will also participate in one-on-one meetings &hellip; Continue reading \"Foghorn Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-participate-in-the-guggenheim-emerging-outlook-biotech-summit\/","og_site_name":"Market Newsdesk","article_published_time":"2026-02-03T12:04:47+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY0NTY2NCM3Mzk5ODc4IzIyMDI4NjI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-participate-in-the-guggenheim-emerging-outlook-biotech-summit\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-participate-in-the-guggenheim-emerging-outlook-biotech-summit\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Foghorn Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit","datePublished":"2026-02-03T12:04:47+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-participate-in-the-guggenheim-emerging-outlook-biotech-summit\/"},"wordCount":241,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-participate-in-the-guggenheim-emerging-outlook-biotech-summit\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY0NTY2NCM3Mzk5ODc4IzIyMDI4NjI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-participate-in-the-guggenheim-emerging-outlook-biotech-summit\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-participate-in-the-guggenheim-emerging-outlook-biotech-summit\/","name":"Foghorn Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-participate-in-the-guggenheim-emerging-outlook-biotech-summit\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-participate-in-the-guggenheim-emerging-outlook-biotech-summit\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY0NTY2NCM3Mzk5ODc4IzIyMDI4NjI=","datePublished":"2026-02-03T12:04:47+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-participate-in-the-guggenheim-emerging-outlook-biotech-summit\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-participate-in-the-guggenheim-emerging-outlook-biotech-summit\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-participate-in-the-guggenheim-emerging-outlook-biotech-summit\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY0NTY2NCM3Mzk5ODc4IzIyMDI4NjI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY0NTY2NCM3Mzk5ODc4IzIyMDI4NjI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-participate-in-the-guggenheim-emerging-outlook-biotech-summit\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Foghorn Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/933531","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=933531"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/933531\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=933531"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=933531"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=933531"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}